Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 3189 (miR-3189) is a primate-specific, non-coding RNA molecule embedded within the intron of the growth differentiation factor 15 (GDF15) gene and regulated by p53. It mainly produces the 3p miRNA (miR-3189-3p), which acts as a potent tumor suppressor by inhibiting cell proliferation, migration, and invasion, and inducing apoptosis in cancer cells. miR-3189 downregulates a broad array of genes involved in cell cycle control and cell survival, in particular targeting mRNAs such as 4E-BP1 (EIF4EBP1), SF3B2, and p63RhoGEF, indirectly reducing oncogene (such as c-MYC) expression. The microRNA exerts these effects through both p53-dependent and p53-independent mechanisms, and its expression is epigenetically regulated, such as by H3K27me3 modification in glioblastoma. miR-3189 is markedly downregulated in several cancers, including glioblastoma and gastric cancer, and experimental restoration of its expression suppresses tumor cell growth, migration, and enhances apoptosis. As a target, it is being explored for therapeutic RNA-based approaches and as a biomarker in oncology. Key references: - miR-3189-3p targets translational regulatory proteins and indirectly inhibits c-MYC; suppresses cell proliferation and promotes apoptosis and distinct metabolic states in breast cancer and glioblastoma. - Downregulation of miR-3189-3p is observed in glioblastoma and gastric cancer, and restoration inhibits key cancer cell phenotypes and tumor aggressiveness. Epigenetic control through PRC2/H3K27me3 silences miR-3189-3p, leading to activation of malignancy-promoting genes such as COL6A2. No approved drugs directly target miR-3189 as of now; strategies involve miRNA mimics and gene therapy approaches. Safety and efficacy profiles are under preclinical investigation.
No direct drugs, but as a microRNA, mechanism is through RNA-induced silencing complex (RISC)-mediated translational inhibition or degradation of target mRNAs; therapeutic strategies may involve miR-3189 mimics
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 3189 (miR-3189).